Skip to main content
Top
Published in: Cancer Immunology, Immunotherapy 6/2023

Open Access 27-02-2023 | NSCLC | Correction

Correction to: Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50%

Authors: E. Pons-Tostivint, P. Hulo, V. Guardiolle, L. Bodot, A. Rabeau, M. Porte, S. Hiret, P. Demontrond, H. Curcio, A. Boudoussier, R. Veillon, M. Mayenga, C. Dumenil, T. Chatellier, P. A. Gourraud, J. Mazieres, J. Bennouna

Published in: Cancer Immunology, Immunotherapy | Issue 6/2023

Login to get access

Excerpt

Correction to: Cancer Immunology, Immunotherapy https://​doi.​org/​10.​1007/​s00262-022-03359-2
Metadata
Title
Correction to: Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50%
Authors
E. Pons-Tostivint
P. Hulo
V. Guardiolle
L. Bodot
A. Rabeau
M. Porte
S. Hiret
P. Demontrond
H. Curcio
A. Boudoussier
R. Veillon
M. Mayenga
C. Dumenil
T. Chatellier
P. A. Gourraud
J. Mazieres
J. Bennouna
Publication date
27-02-2023
Publisher
Springer Berlin Heidelberg
Published in
Cancer Immunology, Immunotherapy / Issue 6/2023
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-023-03405-7

Other articles of this Issue 6/2023

Cancer Immunology, Immunotherapy 6/2023 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine